As TP53 mutations and low expression of miR34a have been associated with worse prognosis in cancer, we compared survival rates of samples with low expression of lncTAM34a (bottom 10th percentile) to control samples in 17 cancer types from TCGA (Supplementary Figure 6)17–19. The gene discussed is TP53; the disease is cancer.